Scientific Program

Sep. 3(Wed)

KSMO Initiatives for Cancer Care Inequity
TBD
Date & Time Sep. 3(Wed), 14:00-16:00 Venue Room D (Walker Hall 2)
Session Details
  1. TBD
    TBD
Education Session 1 (ES01)
Symptom management in advanced cancer: Innovations and best practices
Date & Time Sep. 3 (Wed), 16:10-17:30 Venue Room D (Walker Hall 2)
Session Details
  1. 1. New approach to manage toxicities of novel anticancer drugs
    Hee Jun Kim (Chung-Ang University College of Medicine, Korea)
  2. 2. Pharmacological innovations in symptom control
    Seyoung Seo (Asan Medical Center, Korea)
  3. 3. Advanced nursing approaches: Outpatient nurse-led telephone counseling for cancer symptom management
    Ji Youn Kim (Medical Oncology Clinical Nurse Specialist, Asan Medical Center, Korea)
  4. 4. Integrating clinical research and coordinated care for optimal symptom management
    Hee Kyung Ahn (Samsung Medical Center, Korea)

Sep. 4 (Thu)

ASCO/KSMO Joint Symposium 1 (JS01)
TBD
Date & Time Sep. 4 (Thu), 08:40-10:10 Venue Room A (Vista Hall 1)
Session Details
  1. 1.Towards a deeper understanding of current therapies in gastric cancer – Lessons from translational research
    Samuel Klempner (Massachusetts General Hospital, USA)
  2. 2. Gastroesophageal cancer: Targets, immunotherapy and beyond-global collaboration
    Jeeyun Lee (Samsung Medical Center, Korea)
  3. 3.Landmark trials from keynote trials to destiny trials in GEC: What is next?
    Samuel Cytyrn (Memorial Sloan Kettering Cancer Center, USA)
  4. 4.Her2+ gastric cancer: Time to move forward
    Keun-Wook Lee (Seoul National University Bundang Hospital, Korea)
KCSG/KSMO Joint Symposium 2 (JS02)
Transforming oncology research: AI-powered clinical trials
Date & Time Sep. 4 (Thu), 08:40-10:10 Venue Room B (Vista Hall 3)
Session Details
  1. 1.Clinical research and generative AI
    Hiromizu Takahashi (Juntendo University Urayasu Hospital, Japan)
  2. 2. AI-Driven patient recruitment and trial optimization
    Kenneth Kehl (Dana-Farber Cancer Institute, USA)
  3. 3.Clinical trial design and simulation with AI
    Sandip Pravin Patel (UC San Diego Moores Cancer Center, USA)
  4. 4.Regulatory and ethical considerations in AI-powered clinical trials
    Hannah Kim (Yonsei University College of Medicine, Korea)
Education Session 2 (ES02)
Tumor heterogeneity and single-cell analysis KOREAN
Date & Time Sep. 4 (Thu), 08:40-10:10 Venue Room C (Walker Hall 1)
Session Details
  1. 1. Tumor Heterogeneity
    Jinhyuk Bhin (Yonsei University College of Medicine, Korea)
  2. 2. Tumor-normal single cell atlas (30 cancer types)
    Jong-Eun Park (KAIST, Korea)
  3. 3. Mapping and targeting tumor microenvironment in gastric cancer
    Hoon Hur (Ajou University School of Medicine, Korea)
  4. 4. Deciphering head and neck cancer microenvironment: Single-cell and spatial transcriptomics
    Yun Hak Kim (Pusan National University, Korea)
Scientific Symposium 1 (SS01)
Optimizing the transition to palliative care: Prognostic estimation and communication in oncology
Date & Time Sep. 4 (Thu), 08:40-10:10 Venue Room D (Walker Hall 2)
Session Details
  1. 1. Prognostic estimation for optimal timing of palliative care referrals: From classic to novel
    Yusuke Hiratsuka (Takeda General Hospital, Japan)
  2. 2. Designing structured approaches for prognostic communication and goal of care discussions
    Young Kwang Chae (Northwestern University, USA)
  3. 3. Real world challenges in shared decision-making: Integrating information and values
    Beodeul Kang (CHA Bundang Medical Center, Korea)
  4. 4. Training oncologists in prognostic estimation and communication: Building essential skills for clinical practice
    Eun Mi Nam (Ewha Womans University Seoul Hospital, Korea)
Satellite Symposium 1 (SL01)
TBD
Date & Time Sep. 4 (Thu), 08:40-9:20 Venue Room E (Grand Hall 4)
Session Details
  1. TBD
    TBD
Satellite Symposium 2 (SL02)
Clinical values of Lorviqua(Lorlatinib) as a 1st line treatment for ALK positive mNSCLC patients
Date & Time Sep. 4 (Thu), 9:30-10:10 Venue Room E (Grand Hall 4)
Session Details
  1. Redefining first-line standards: Lorlatinib in ALK+ mNSCLC
    Sun Min Lim(Yonsei University College of Medicine, Korea )
Plenary Lecture 1 (PL01)
Breaking new ground: Innovative cancer vaccine therapies
Date & Time Sep. 4 (Thu), 10:40-11:20 Venue Room A (Vista Hall 1)
Session Details
  1. Breaking new ground: Innovative cancer vaccine therapies
    Patrick Ott (Dana-Farber Cancer Institute, USA)
Luncheon Symposium 1 (LS01)
TBD
Date & Time Sep. 4 (Thu), 11:30-12:10 Venue Room A (Vista Hall 1)
Session Details
  1. TBD
     
Luncheon Symposium 2 (LS02)
TBD
Date & Time Sep. 4 (Thu), 11:30-12:10 Venue Room B (Vista Hall 3)
Session Details
  1. TBD
     
Luncheon Symposium 3 (LS03)
TBD
Date & Time Sep. 4 (Thu), 11:30-12:10 Venue Room A (Vista Hall 1)
Session Details
  1. TBD
     
Luncheon Symposium 4 (LS04)
Expanding the Horizon of HER2 Therapy: ADC Treatment for breast cancer patients across HER2 expression spectrum
Date & Time Sep. 4 (Thu), 11:30-12:10 Venue Room D (Walker Hall 2)
Session Details
  1. Expanding the horizon of HER2 therapy: ADC treatment for breast cancer patients across HER2 expression spectrum
    Heejung Chae (Seoul National University Bundang Hospital, Korea)
Luncheon Symposium 5 (LS05)
TBD
Date & Time Sep. 4 (Thu), 11:30-12:10 Venue Room E (Grand Hall 4)
Session Details
  1. TBD
     
Scientific Symposium 2 (SS02)
Revolutionizing GI cancer care with next-generation modalities
Date & Time Sep. 4 (Thu), 12:20-13:50 Venue Room A (Vista Hall 1)
Session Details
  1. 1. CLDN18.2: New target for gastric and pancreatic cancer
    Zev A. Weinberg (UCLA, USA)
  2. 2. Novel IO combinations for GI cancers: Beyond PD-1/PD-L1 and CTLA4
    Minsuk Kwon (Samsung Medical Center, Korea)
  3. 3. Emerging cell-based therapy for GI cancers
    Changsong Qi (Peking University Cancer Hospital and Institute, China)
  4. 4. Novel therapeutic vaccine for GI cancers
    Tetsuya Nakatsura (National Cancer Center, Japan)
Education Session 3 (ES03)
Cancer survivorship: Shifting paradigms in care KOREAN
Date & Time Sep. 4 (Thu), 12:20-13:50 Venue Room B (Vista Hall 3)
Session Details
  1. 1. Surviving with emerging long-term toxicities
    Yun-Gyoo Lee (Kangbuk Samsung Hospital, Korea)
  2. 2. Genetic counseling for cancer survivors
    Ji Soo Park (Cancer Prevention Center, Yonsei Cancer Center, Korea)
  3. 3. Restoring emotional strength after cancer: Psychological interventions
    Seockhoon Chung (Asan Medical Center, Korea)
  4. 4. Empowered survivorship through digital health
    Juhee Cho (Samsung Comprehensive Cancer Center, Korea)
Scientific Symposium 3 (SS03)
How shall we treat RARE cancer in the era of precision medicine : Progress and challenges ahead
Date & Time Sep. 4 (Thu), 12:20-13:50 Venue Room C (Walker Hall 1)
Session Details
  1. 1. How can we facilitate personalized trial for rare cancers: KCSG experience
    Bhumsuk Keam (Seoul National University Hospital, Korea)
  2. 2. Role of (pre)clinical trials in rare cancer: Focusing on adenoid cystic carcinoma
    Hyunseok Kang (UCSF, USA)
  3. 3. Tracing molecular evolution of glioblastoma: Will it make some changes?
    Michael Lim (Standford University, USA)
  4. 4. Integration of immune-oncology in treatment of GBM: Recent updates and future direction
    Jong Bae Park (National Cancer Center, Korea)
KOSRO/KSMO Joint Symposium 3 (JS03)
Optimization of neoadjuvant/adjuvant treatment
Date & Time Sep. 4 (Thu), 12:20-13:50 Venue Room D (Walker Hall 2)
Session Details
  1. 1. Breast adjuvant RT (including EUROPA)
    Bruno Meduri (Azienda Provinciale per i Servizi Sanitari (APSS), Italy)
  2. 2. Rectal cancer TNT
    Deborah Schrag (Memorial Sloan Kettering Cancer Center, USA)
  3. 3. NSCLC neoadjuvant regimen
    Jang Ho Cho (Gachon University Gil Medical Center, Korea)
  4. 4. Radiotherapy for sacroma
    Jeong Il Yu (Samsung Medical Center, Korea)
Satellite Symposium 3 (SL03)
TBD
Date & Time Sep. 4 (Thu), 12:20-13:00 Venue Room E (Grand Hall 4)
Session Details
  1. TBD
     
Satellite Symposium 4 (SL04)
TBD
Date & Time Sep. 4 (Thu), 12:20-13:00 Venue Room E (Grand Hall 4)
Session Details
  1. TBD
     
ESMO/KSMO Joint Symposium 4 (JS04)
ESMO guideline and the implementation in Asian Pacific region
Date & Time Sep. 4 (Thu), 14:00-15:30 Venue Room A (Vista Hall 1)
Session Details
  1. 1. Case presentation
    Kyung-Hun Lee (Seoul National University Hospital, Korea)
  2. 2. Critical analysis and presentation of the ESMO Guideline early-onset breast cancer, with MCBS and ESCAT
    TBD
  3. 3. “Asian” perspectives on genetics, practice and applicability: KOSMOS
    Jee Hyun Kim (Seoul National University Bundang Hospital, Korea)
  4. 4. Case presentation
    TBD
  5. 5. Critical analysis and presentation of the ESMO Guideline - Kidney cancer, with ESMO-MCBS and ESCAT
    Matthew Young (Barts Cancer Institute, Queen Mary University of London, UK)
  6. 6. TBD
    TBD
KSSO/KSMO Joint Symposium 5 (JS05)
Omit surgery in GI cancer treatment
Date & Time Sep. 4 (Thu), 14:00-15:30 Venue Room B (Vista Hall 3)
Session Details
  1. 1. Omit surgery in pancreatic cancer: Can systemic therapy replace resection?
    Kosuke Kobayashi (Cancer Institute Hospital, Japan)
  2. 2. Omit surgery in rectal cancer: Is watch-and-wait a viable long-term strategy?
    Minsu Kang (Seoul National University Bundang Hospital, Korea)
  3. 3. Omit surgery in gastric cancer: When can we rely on non-surgical therapy alone?
    Jaemin Jo (Jeju National University Hospital, Korea)
  4. 4. Local therapies vs surgery in hepatocellular carcinoma: Is resection always necessary?
    Kenneth Chok (The Chinese University of Hong Kong, Hong Kong)
Education Session 4 (ES04)
Toxicity management in Antibody-Drug Conjugates (ADCs) KOREAN
Date & Time Sep. 4 (Thu), 14:00-15:30 Venue Room C (Walker Hall 1)
Session Details
  1. 1. Drug properties of antibody-drug conjugates
    In Hae Park (Korea University Guro Hospital, Korea)
  2. 2. Overview of toxicities of ADCs (including hematologic toxicities)
    Han Jo Kim (Soonchunhyang University Cheonan Hospital, Korea)
  3. 3. Pulmonary toxicities from ADCs
    Jimyung Park (Seoul National University Hospital, Korea)
  4. 4. Ocular toxicities from ADCs
    Chang Ho Yoon (Seoul National University Hospital, Korea)
Scientific Symposium 4 (SS04)
Current trends and future perspectives in GU oncology
Date & Time Sep. 4 (Thu), 14:00-15:30 Venue Room D (Walker Hall 2)
Session Details
  1. 1. Mechanism-based treatment strategies in RCC
    Ramaprasad Srinivasan (National Cancer Institute, USA)
  2. 2. Biomarkers in RCC: Current status and future direction
    David Braun (Yale School of Medicine, USA)
  3. 3. Antibody-drug conjugate in advanced urothelial carcinoma: Established & emerging drugs
    Hyeon-Su Im (Ulsan University Hospital, Korea)
  4. 4. How can we integrate PARP inhibitors in treatment of prostate cancer?
    Hyunho Kim (The Catholic University of Korea St. Vincent's Hospital, Korea)
Satellite Symposium 5 (SL05)
Advances and innovations in ES-SCLC treatment
Date & Time Sep. 4 (Thu), 14:00-14:40 Venue Room E (Grand Hall 4)
Session Details
  1. Targeting DLL3 with BiTE therapy: A new paradigm in SCLC treatment
    Jeonghwan Youk(Seoul National University Hospital, Korea)
Satellite Symposium 6 (SL06)
TBD
Date & Time Sep. 4 (Thu), 14:50-15:30 Venue Room E (Grand Hall 4)
Session Details
  1. TBD
    TBD
Plenary Lecture 2 (PL02)
Cancer cachexia: Transition from science to practice
Date & Time Sep. 4 (Thu), 15:40-16:20 Venue Room A (Vista Hall 1)
Session Details
  1. Cancer cachexia: Transition from science to practice
    Jeffrey Crawford (Duke Cancer Center, USA)
Scientific Symposium 5 (SS05)
Current Insights and future directions of MBC treatment
Date & Time Sep. 4 (Thu), 16:20-17:50 Venue Room A (Vista Hall 1)
Session Details
  1. 1. Targeting PTEN/PI3K/AKT pathway: Roles and limitations
    Carlos Arteaga (UT Southwestern Harold C. Simmons Cancer Center, USA)
  2. 2. Optimizing anti-Her2 treatment in the era of ADCs
    Jieun Park (Jeju National University Hospital, Korea)
  3. 3. Advancing treatment frontiers in TNBC : Beyond immunotherpay
    Kyong Hwa Park (Korea University Anam Hospital, Korea)
  4. 4. Managing oligometastasis- Is it curable?
    Gun Min Kim (Yonsei University College of Medicine, Korea)
Oral Presentation 1 (OP01)
TBD
Date & Time Sep. 4 (Thu), 16:20-17:20 Venue Room B (Vista Hall 3)
Session Details
  1. TBD
    TBD
Scientific Symposium 6 (SS06)
Clinical promise of ctDNA-based MRD testing in solid tumors
Date & Time Sep. 4 (Thu), 16:20-17:50 Venue Room C (Walker Hall 1)
Session Details
  1. 1. ctDNA MRD for solid tumors: Translating clinical evidence into practice
    Yongjun Cha (IMB Dx, Korea)
  2. 2. ctDNA MRD for solid tumors: Overcoming technical challenges for broader clinical implementation
    Aadel Chaudhuri (Mayo Clinic, USA)
  3. 3. Striving for a quantum leap on Molecular Residual Disease (MRD) clinical development: Insights from CIRCULATE-JAPAN & SCRUM- MONSTAR
    Takayuki Yoshino (National Cancer Center Hospital East, Japan)
  4. 4. Leveraging ctDNA MRD in clinical trials and drug development: Opportunities and outlook
    Aparna Parikh (Massachusetts General Hospital, USA)
KSR/KSMO Joint Symposium 6 (JS06)
Radiomics Revolution: AI and Imaging in Cancer Care
Date & Time Sep. 4 (Thu), 16:20-17:50 Venue Room D (Walker Hall 2)
Session Details
  1. 1. The role of CT-determined sarcopenia in predicting cancer treatment outcomes
    Young Saing Kim (Gachon University Gil Medical Center, Korea)
  2. 2. Using CT-derived body composition indices to predict CDK4/6 inhibitor response in breast cancer patients
    Min Hwan Kim (Yonsei Cancer Center, Korea)
  3. 3. Radiomics and AI in lung cancer
    Guillaume Chassagnon (Université Paris Cité, France)
  4. 4. Radiomics and AI in neuro-oncology
    Sung Soo Ahn (Yonsei University College of Medicine, Korea)
Satellite Symposium 7 (SL07)
TBD
Date & Time Sep. 4 (Thu), 16:20-17:00 Venue Room E (Grand Hall 4)
Session Details
  1. TBD
     
Satellite Symposium 8 (SL08)
Later-line treatment for mCRC patients (Draft)
Date & Time Sep. 4 (Thu), 16:20-17:00 Venue Room E (Grand Hall 4)
Session Details
  1. Treatment for metastatic colorectal cancer : Focused on FTD/TPI (TBD)
    Jwa Hoon Kim (Korea University Anam Hospital, Korea)

Sep. 8 (Fri)

JSMO/KSMO Joint Symposium 7 (JS07)
The new standard therapy in solid tumors : The combination of immunotherapies
Date & Time Sep. 5 (Fri), 08:40-10:10 Venue Room A (Vista Hall 1)
Session Details
  1. 1. Frontline therapy in MSI-H metastatic colorectal cancer
    Junho Lee (Kyung Hee University Hospital, Korea)
  2. 2. Frontline therapy in metastatic hepatocellular carcinoma
    Hong sik Kim (Chungbuk National University Hospital, Korea)
  3. 3. Preoperative therapy (Neoadjuvant therapy) in melanoma
    Kenjiro Namikawa (National Cancer Center Hospital, Tokyo, Japan)
  4. 4. Preoperative and frontline therapy in breast cancer (TNBC)
    Kenji Tamura (Shimane University Hospital, Japan)
Education Session 5 (ES05)
Advance of technology - Artificial intelligence in oncology KOREAN
Date & Time Sep. 5 (Fri), 08:40-10:10 Venue Room B (Vista Hall 3)
Session Details
  1. 1. Introduction: Artificial intelligence in oncology
    Chanyoung Ock (Lunit, Korea)
  2. 2. Clinical application of radiology-based AI model for breast cancer: Current and future
    Eunkyung Kim (Yonsei University College of Medicine, Korea)
  3. 3. Clinical application of pathology-based AI model: Current and future
    Yoon Jin Cha (Gangnam Severance Hospital, Korea)
  4. 4. LLM based medical research
    Jeong Moo Lee (Seoul National University Hospital, Korea)
Scientific Symposium 7 (SS07)
Novel opportunities to target cancer: Emerging strategies in molecular oncology
Date & Time Sep. 5 (Fri), 08:40-10:10 Venue Room C (Walker Hall 1)
Session Details
  1. 1. Exploring the cell death phenotypic landscape for cancer
    Scott J. Dixon (Stanford University, USA)
  2. 2. Repurposing cardiac drugs beta-blockers for cancer treatment
    Erica Sloan (Monash University, Australia)
  3. 3. Targeting metastatic cancer via synthetic lethality
    Mi-Young Kim (KAIST, Korea)
  4. 4. Application of space medicine for lung cancer
    Hargsoon Yoon (Norfolk State University, USA)
KSP/KSMO Joint Symposium 8 (JS08)
Biomarker for ADC
Date & Time Sep. 5 (Fri), 08:40-10:10 Venue Room D (Walker Hall 2)
Session Details
  1. 1. CDx update and future strategy for oncology
    Jan Trøst Jørgensen (Dx-Rx Institute, Fredensborg, Denmark)
  2. 2. Biomakrer development for ADC
    Yoon-La Choi (Samsung Medical Center, Korea)
  3. 3. Recent optimization of ADC CDx : FOLR1 IHC
    Gian Franco Zannoni(Università Cattolica del Sacro Cuore, Italy)
  4. 4. Application of AI for biomarker interpretation
    Tae-Yeong Kwak (Deep Bio Inc., Korea)
Satellite Symposium 9 (SL09)
TBD
Date & Time Sep. 5 (Fri), 08:40-9:20 Venue Room E (Grand Hall 4)
Session Details
  1. TBD
    TBD
Satellite Symposium 10 (SL10)
Recent clinical data and real-world case updates on Opdivo in gastric cancer first-line treatment
Date & Time Sep. 5 (Fri), 09:30-10:10 Venue Room E (Grand Hall 4)
Session Details
  1. Recent clinical data and real-world case updates on Opdivo in gastric cancer first-line treatment
    Jaewon Hyung (Asan Medical Center, Korea)
Plenary Lecture 3 (PL03)
Advances in chemotherapy for gastric cancer- Future perspectives
Date & Time Sep. 5 (Fri), 10:30-11:10 Venue Room A (Vista Hall 1)
Session Details
  1. Advances in chemotherapy for gastric cancer- Future perspectives
    Kohei Shitara (National Cancer Center Hospital East, Japan)
Luncheon Symposium 6 (LS06)
TBD
Date & Time Sep. 5 (Fri), 11:30-12:10 Venue Room A (Vista Hall 1)
Session Details
  1. TBD
     
Luncheon Symposium 7 (LS07)
From mTNBC to HR+/HER2- mBC: Sacituzumab Govetican leads the way with proven survival benefit
Date & Time Sep. 5 (Fri), 11:30-12:10 Venue Room B (Vista Hall 3)
Session Details
  1. From mTNBC to HR+/HER2- mBC: Sacituzumab Govetican leads the way with proven survival benefit
    Dae-Won Lee (Seoul National University Hospital, Korea)
Luncheon Symposium 8 (LS08)
Game changer in GC treatment: New hope for CLDN18.2 positive patients
Date & Time Sep. 5 (Fri), 11:30-12:10 Venue Room C (Walker Hall 1)
Session Details
  1. The breakthrough in gastric cancer: VYLOY new hope for CLDN18.2 positive patients (TBD)
    Choong-kun Lee (Yonsei Cancer Center, Korea)
Luncheon Symposium 9 (LS09)
Treatment unmet needs in HR+/HER2- early breast cancer & recent clinical evidence of Ribociclib
Date & Time Sep. 5 (Fri), 11:30-12:10 Venue Room D (Walker Hall 2)
Session Details
  1. Ribociclib: Paving the future of early breast cancer treatment (TBD)
    Jee Hyun Kim (Seoul National University Bundang Hospital, Korea)
Luncheon Symposium 10 (LS10)
Personalized treatment to maximize outcomes for CCA : Focused on Ivosidenib
Date & Time Sep. 5 (Fri), 11:30-12:10 Venue Room E (Grand Hall 4)
Session Details
  1. Exploring long-term treatment outcomes with Ivosidenib in CCA (TBD)
    Beodeul Kang (CHA Bundang Medical Center, Korea)
ASCO/KSMO Joint Symposium 9 (JS09)
TBD
Date & Time Sep. 5 (Fri), 12:20-13:50 Venue Room A (Vista Hall 1)
Session Details
  1. 1. NGS: Should all metastatic cancer patients receive NGS as part of practice: US perspectives
    Steve Maron (Memorial Sloan Kettering Cancer Center, USA)
  2. 2. NGS: Should all metastatic cancer patients receive NGS as part of practice: Korean perspectives
    Sung Hee Lim (Samsung Medical Center, Korea)
  3. 3. NGS benefits biliary tract cancer patients
    Haley Ellis (Massachusetts General Hospital, USA)
  4. 4. NGS benefits rare cancer patients
    Hyo song Kim (Yonsei University College of Medicine, Korea)
Oral Presentation 2 (OP02)
TBD
Date & Time Sep. 5 (Fri), 12:20-13:20 Venue Room B (Vista Hall 3)
Session Details
  1. TBD
    TBD
Multi-Disciplinary Case Discussion (MDCD)
Personalized treatment strategies for oligometastatic patients in the new era of cancer therapeutics KOREAN
Date & Time Sep. 5 (Fri), 12:20-13:50 Venue Room C (Walker Hall 1)
Session Details
  1. 1. Oligometastasis 분류 및 이에 따른 LCT 역할 차이
    Chai Hong Rim (Korea University College of Medicine, Korea)
  2. 2. Integrating local and systemic therapies for oligometastatic patients in the new era of novel cancer treatments
    In Hee Lee (Kyungpook National University Chilgok Hospital, Korea)
  3. 3. Biomarkers in oligometastasis: Current insights and future directions
    Dae-Won Lee (Seoul National University College of Medicine, Korea)
  4. 4. Spine SBRT
    Hwa Kyung Byun (Yongin Severance Hospital, Korea)
Scientific Symposium 8 (SS08)
Combinatory strategy to enhance immune checkpoint response
Date & Time Sep. 5 (Fri), 12:20-13:50 Venue Room D (Walker Hall 2)
Session Details
  1. 1. Optimal immunotherapy combination strategies for hepatobiliary cancer
    Changhoon Yoo (Asan Medical Center, Korea)
  2. 2. Recent advances of bispecific antibody for cancer immunotherapy
    Sangmi Lee (ABL Bio., Korea)
  3. 3. Novel ADCs and immune modulating agents to overcome immunotherapy resistance
    Toshio Shimizu (Kansai Medical University Hospital, Osaka, Japan)
  4. 4. Inducing anti-tumor immune response by radiation therapy
    Kyung Hwan Kim (Yonsei Cancer Center, Korea)
Satellite Symposium 11 (SL11)
TBD
Date & Time Sep. 5 (Fri), 12:20-13:00 Venue Room E (Grand Hall 4)
Session Details
  1. TBD
    TBD
Satellite Symposium 12 (SL12)
From data to practice: Optimizing ADC + IO in advanced UC (TBD)
Date & Time Sep. 5 (Fri), 13:10-13:50 Venue Room E (Grand Hall 4)
Session Details
  1. From Data to Practice: Optimizing ADC + IO in advanced UC (TBD)
    Minsuk Kwon (Samsung Medical Center, Korea)
Plenary Lecture 4 (PL04)
Biomarkers to predict efficacy and toxicity of antibody drug conjugates in breast cancer
Date & Time Sep. 5 (Fri), 14:00-14:40 Venue Room A (Vista Hall 1)
Session Details
  1. Biomarkers to predict efficacy and toxicity of antibody drug conjugates in breast cancer
    Giuseppe Curigliano (European Institute of Oncology, IRCCS and Università degli Studi di Milano, Italy)
ESMO/KSMO Joint Symposium 10 (JS10)
How to streamline initiatives for optimising oncology practice
Date & Time Sep. 5 (Fri), 14:50-16:20 Venue Room A (Vista Hall 1)
Session Details
  1. 1. ESMO ETAC-Tumour agnostic oncology: Drug development trends and mindsets
    Fernanda Mosele (Gustave Roussy, France)
  2. 2. “Asian” perspectives on drug development challenges and breakthroughs
    Sang Joon Shin (Yonsei Cancer Center, Korea)<
  3. 3. Generative AI for treatment decisions
    Titus Brinker (German Cancer Research Center, Germany)
  4. 4. Generative AI and clinical decision support system utility in the hospital
    Wonchul Cha (Samsung Medical Center, Korea)
Scientific Symposium 9 (SS09)
Real-world challenges in GI oncology: Navigating complex treatment decisions
Date & Time Sep. 5 (Fri), 14:50-16:20 Venue Room C (Walker Hall 1)
Session Details
  1. 1. How can we adopt immunotherapy for MSS CRC?
    Hyun Jin Bang (Chonnam National University Hwasun Hospital, Korea)
  2. 2. Systemic treatment strategies for HCC with poor liver function
    David James Pinato (Hammersmith Hospital, UK)
  3. 3. Who benefits from neoadjuvant chemotherapy in resectable pancreatic cancer?
    Choong-kun Lee (Yonsei Cancer Center, Korea)
  4. 4. GI cancer with peritoneal metastasis: Hard-to-treat disease entity
    Raghav Sundar (Yale School of Medicine, USA)
Scientific Symposium 10 (SS10)
Revealing immune response and resistance through spatial profiling of NSCLC microenvironment
Date & Time Sep. 5 (Fri), 14:50-16:20 Venue Room D (Walker Hall 2)
Session Details
  1. 1. Overview of tumor microenvironment of lung cancer
    Jaemoon Koh (Seoul National University Hospital, Korea)
  2. 2. AI-assisted TIL analysis as predictive biomarker for ICI in NSCLC
    Mehrdad Rakaee (Institute for Cancer Research, Oslo University Hospital, Norway)
  3. 3. Revealing immune response and resistance through spatial profiling of NSCLC
    Antoine Italiano (DITEP, Gustave Roussy, France)
  4. 4. Spatial interactomics: Mapping protein interplay to fight cancer
    Ece D. Gamsiz Uzun (The Warren Alpert Medical School of Brown University, USA)
Satellite Symposium 13 (SL13)
Redefining PI3K pathway inhibitors in HR+ breast cancer with Inavolisib
Date & Time Sep. 5 (Fri), 14:50-15:30 Venue Room E (Grand Hall 4)
Session Details
  1. Redefining PI3K pathway inhibitors in HR+ breast cancer with Inavolisib
    Seock-Ah Im (Seoul National University Hospital, Korea)
Satellite Symposium 14 (SL14)
Evolving management of mUC in Korea: Case-based insights and treatment strategies
Date & Time Sep. 5 (Fri), 15:40-16:20 Venue Room E (Grand Hall 4)
Session Details
  1. 1. The evolution of mUC treatment in Korea: The significance of 1L maintenance
    In Ho Kim (The Catholic University of Korea Seoul St. Mary’s Hospital, Korea)
  2. 2. Treatment journey in mUC; Case-based learning
    Hongsik Kim (Chungbuk National University Hospital, Korea)